Merck & Company (MRK) 59.99 $MRK
OncoSec Medical Expands Legal Team, Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary
Business Wire - 24 mins ago
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has appointed Sheela Mohan-Peterson, J.D., M.S. to the position of General Counsel and Corporate Secretary. In this newly created role, she will be responsible for leading the Company's global legal strategy and guiding the continued expansion of its intellectual property portfolio. Ms. Mohan-Peterson will be supported by an experienced internal legal team that includes legal associate and paralegal positions.
Dow Jones (DJIA) Today: Merck (MRK) Higher
at The Street - Tue Sep 16, 1:00PM CDT
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting a 34-cent gain (+0.6%) bringing the stock to $59.86.
Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis
PR Newswire Europe - Tue Sep 16, 12:53PM CDT
DUBLIN, Sept. 16, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/jq2qvt/global_animal] has announced the addition of the "Global Animal Vaccines Market 2014-2018" [http://www.researchandmarkets.com/research/jq2qvt/global_animal] report to their offering.
Merck (MRK) Crosses Pivot Point Support at $59.35
Comtex SmarTrend(R) - Tue Sep 16, 9:01AM CDT
Shares of Merck (NYSE:MRK) opened today below their pivot of $59.67 and have already reached the first level of support at $59.35. Should the shares continue to fall, the support pivots of $59.18 and $58.69 will be of interest.
Global Hepatitis C Market Report 2014-2018: Leading Vendors are F. Hoffmann-La Roche, Gilead Sciences, J&J, Merck & Vertex Pharmaceuticals
M2 - Tue Sep 16, 8:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rlbk3z/global_hepatitis) has announced the addition of the "Global Hepatitis C Market 2014-2018" report to their offering. The Global Hepatitis C market to grow at a CAGR of 19.2% over the period 2013-2018 This report covers the present scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through sales of various drugs administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus. One of the emerging trends in the market is the emergence of Interferon -free regimens. Various IFN-free regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause fewer side effects than currently approved therapies. According to the report, the launch of direct-acting antivirals is one of the major drivers of the market. These are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN. They increase the efficacy of treatment and reduce the duration of therapy. Further, the report states that the side effects of current therapies are one of the major challenges in the market. Currently, approved drugs for hepatitis C are associated with poor tolerability and lower patient compliance rates. This, in turn, decreases the market revenue of the currently approved drugs. Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - Johnson & Johnson - Merck - Vertex Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Key Marketed Drugs for Treatment of Chronic Hepatitis C - Market Segmentation by MOA - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/rl..._hepatitis
Animal Healthcare Market - Global Industry Analysis 2014 - 2019: Segment, Animal type and Regional Analysis
M2 - Tue Sep 16, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/knrxpc/animal_healthcare) has announced the addition of the "Animal Healthcare Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019 Market" report to their offering. The global animal healthcare market is growing due to the increasing animal population of both types: companion and production. Companion animals are those which people tame or adopt for companionship, house/office guards and production animals are raised for meat and milk-related products. The new diseases in animals and their transfer to humans via their product consumption and companionship are also propelling the animal healthcare market globally. However, some challenges have emerged in the form of regulations against the excess use of antibiotics in production animals, and legislations and protest of animal activists and institutions against animal research. The animal healthcare market is very competitive with the top ten players accounting for about 75% of the market and every company focusing on research and development to produce better pharmaceutical and vaccine products for the existing diseases. The animal healthcare market is categorized under three broad segments, namely feed additives, pharmaceuticals and vaccines. Feed additives can be categorized as nutritional feed additives and medicinal feed additives. Nutritional feed additives comprise amino acids, minerals and vitamins and are used for production animals for their optimal growth. Medicinal feed additives comprise hormones, enzymes, immune-modulators, probiotics and prebiotics and feed acidifiers which target specific diseases in production and companion animals. Pharmaceutical products mainly include endoparasiticides, ectoparasiticides, endectocides, antibiotics, anti-inflammatories and medicines for reproductive problems. Vaccines make animals disease-immune for a particular disease. In biological terms, vaccination against a particular pathogen aims to mimic the development of naturally acquired immunity by inoculation of non-pathogenic but immunogenic components of that pathogen.omponents of that pathogen. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Animal Healthcare Market - Industry Overview Chapter 4 Global Animal Healthcare Market: By Product Segment Chapter 5 Global Animal Healthcare Market: By Animal Type Chapter 6 Global Animal Healthcare Market: By Region Chapter 7 Competitive Landscape Chapter 8 Company Profiles - Bayer AG - Boehringer Ingelheim GmbH - Ceva Sant? Animale - Elanco Products Company - MERIAL Limited - Merck & Co., Inc. - Novartis Animal Health Inc. - Virbac SA - V?toquinol SA - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/kn...healthcare
Merck Serono to Broaden Its General Medicines Portfolio in Emerging Markets with Affordable, High-Quality Medicines
Business Wire - Tue Sep 16, 4:00AM CDT
--Lupin will provide product dossiers and supply finished products for portfolio expansion
Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis
Business Wire - Mon Sep 15, 12:30PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Merck's investigational once-weekly cathepsin K inhibitor. In the Long-Term Odanacatib Fracture Trial (LOFT), odanacatib met its primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with placebo. The results from this trial were presented today at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Houston, Texas.
New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma
PR Newswire - Mon Sep 15, 8:15AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Medtronic, Inc. (NYSE: MDT), Pharmacyclics Inc. (NASDAQ: PCYC) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6464-100free.
BeiGene Receives Clinical Milestone Payment for Development of BGB-290
Business Wire - Mon Sep 15, 7:00AM CDT
BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-290, an investigational poly (ADP-ribose) polymerase (PARP) inhibitor candidate currently in Phase 1 development. The milestone triggers a US$ 9 million payment from Merck to BeiGene.
Merck Millipore Recognized for Technologically Advanced Products by R&D Magazine
Business Wire - Mon Sep 15, 1:00AM CDT
Merck Millipore, the Life Science division of Merck, announced it has received two R&D Magazine 100 Awards for innovative products released to market in 2014. The 52nd Annual R&D Awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.
Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies
at The Street - Fri Sep 12, 10:32AM CDT
Here are some numbers to help investors make prudent decisions when allocating cash to 11 big-cap pharmaceutical companies.
Dow 30 Stock Roundup: Boeing Bags $11B Order, GE to Sell Appliance Unit to Electrolux - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Sep 12, 9:50AM CDT
The Dow had a dismal week as energy prices continued to dominate proceedings.
Research and Markets: Global Asthma Market 2014-2018: Leading Vendors are AstraZeneca, F. Hoffmann-La Roche, GSK, Merck & Novartis
Business Wire - Fri Sep 12, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/572r9k/global_asthma) has announced the addition of the "Global Asthma Market 2014-2018" report to their offering.
Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer
PR Newswire Europe - Fri Sep 12, 9:08AM CDT
DARMSTADT, Germany, September 12, 2014 /PRNewswire/ --
Global Animal Health Market 2014-2018: Key Vendors are Bayer, Elanco, Merck Animal Health, Merial and Zoetis
PR Newswire Europe - Fri Sep 12, 7:02AM CDT
DUBLIN, Sept. 12, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/jr5z25/global_animal] has announced the addition of the "Global Animal Health Market 2014-2018" [http://www.researchandmarkets.com/research/jr5z25/global_animal] report to their offering.
Global Asthma Market 2014-2018: Leading Vendors are AstraZeneca, F. Hoffmann-La Roche, GSK, Merck & Novartis
M2 - Fri Sep 12, 6:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/69j7kn/global_asthma) has announced the addition of the "Global Asthma Market 2014-2018" report to their offering. The Global Asthma Market to grow at a CAGR of 4.5% over the period 2013-2018. One trend emerging in this market is the use of combination therapies for the treatment of asthma patients. These therapies can improve patient condition in persistent asthma and act via reduction of the symptoms by controlling inflammation in the respiratory tract. According to the report, the major driving factor of this market is a rise in the prevalence of environmental pollution. Globalization and urbanization coupled with industrialization lead to an increase in environmental pollution. Further, the report states that the unknown etiology of the disease is a major challenge to the market which makes it difficult for drug manufacturers to develop a remedy. The underlying causes of asthma are not completely understood, though allergens and pollutants worsen the condition of the patient. This report covers the present scenario and the growth prospects of the Global Asthma market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various class of drugs used in the treatment of asthma: - Bronchodilators - Leukotriene antagonists - Mast cell stabilizers - Immunosuppressants Key Vendors - AstraZeneca - F. Hoffmann-La Roche - GlaxoSmithKline - Merck - Novartis Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Class of Drugs - Global Bronchodilators Market - Global Leukotriene Antagonists Market - Global Mast Cell Stabilizers Market - Global Immunosuppressants Market - Global Combination of ICS/LABA Market - Global Other Asthma Drugs Market - Geographical Segmentation - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Pipeline Portfolio - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/69...bal_asthma
Global Animal Vaccines Market 2014-2018: Leading Vendors are Bayer HealthCare, Elanco Animal Health, Merck Animal Health, Novartis Animal Health, Sanofi & Zoetis
M2 - Fri Sep 12, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/56q7l6/global_animal) has announced the addition of the "Global Animal Vaccines Market 2014-2018" report to their offering. The Global Animal Vaccines market to grow at a CAGR of 8.25% over the period 2013-2018 This report covers the present scenario and the growth prospects of the Global Animal Vaccines market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various animal vaccines. In terms of vaccines types, the Global Animal Vaccines market can be segmented into six: Companion Animal Vaccines, Livestock Vaccines, Porcine Vaccines, Poultry Vaccines, Equine Vaccines, and Other Animal Vaccines. One of the major emerging trends in this market is an increase in acquisitions. Vendors have been focusing on acquisitions to increase their foothold in the market through increased investments. According to the report, one of the main drivers of this market is an increase in the prevalence of animal diseases worldwide, in both developed and developing countries. As a result, the use of animal vaccines has increased. The increasing susceptibility of animals to chronic diseases has driven the revenue growth of this market to a great extent. Further, the report states that one of the main challenges that the market faces is a rise in the maintenance costs of vaccines. Though the animal vaccines have numerous benefits, the high cost of these vaccines hinders acceptability among end-users. Key Vendors - Bayer HealthCare - Elanco Animal Health - Merck Animal Health - Novartis Animal Health - Sanofi - Zoetis Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Products - Market Segmentation by Technology - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/56...bal_animal
OncoSec Medical Expands Legal Team, Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary
Business Wire - 24 mins ago
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has appointed Sheela Mohan-Peterson, J.D., M.S. to the position of General Counsel and Corporate Secretary. In this newly created role, she will be responsible for leading the Company's global legal strategy and guiding the continued expansion of its intellectual property portfolio. Ms. Mohan-Peterson will be supported by an experienced internal legal team that includes legal associate and paralegal positions.
Dow Jones (DJIA) Today: Merck (MRK) Higher
at The Street - Tue Sep 16, 1:00PM CDT
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting a 34-cent gain (+0.6%) bringing the stock to $59.86.
Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis
PR Newswire Europe - Tue Sep 16, 12:53PM CDT
DUBLIN, Sept. 16, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/jq2qvt/global_animal] has announced the addition of the "Global Animal Vaccines Market 2014-2018" [http://www.researchandmarkets.com/research/jq2qvt/global_animal] report to their offering.
Merck (MRK) Crosses Pivot Point Support at $59.35
Comtex SmarTrend(R) - Tue Sep 16, 9:01AM CDT
Shares of Merck (NYSE:MRK) opened today below their pivot of $59.67 and have already reached the first level of support at $59.35. Should the shares continue to fall, the support pivots of $59.18 and $58.69 will be of interest.
Global Hepatitis C Market Report 2014-2018: Leading Vendors are F. Hoffmann-La Roche, Gilead Sciences, J&J, Merck & Vertex Pharmaceuticals
M2 - Tue Sep 16, 8:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rlbk3z/global_hepatitis) has announced the addition of the "Global Hepatitis C Market 2014-2018" report to their offering. The Global Hepatitis C market to grow at a CAGR of 19.2% over the period 2013-2018 This report covers the present scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through sales of various drugs administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus. One of the emerging trends in the market is the emergence of Interferon -free regimens. Various IFN-free regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause fewer side effects than currently approved therapies. According to the report, the launch of direct-acting antivirals is one of the major drivers of the market. These are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN. They increase the efficacy of treatment and reduce the duration of therapy. Further, the report states that the side effects of current therapies are one of the major challenges in the market. Currently, approved drugs for hepatitis C are associated with poor tolerability and lower patient compliance rates. This, in turn, decreases the market revenue of the currently approved drugs. Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - Johnson & Johnson - Merck - Vertex Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Key Marketed Drugs for Treatment of Chronic Hepatitis C - Market Segmentation by MOA - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/rl..._hepatitis
Animal Healthcare Market - Global Industry Analysis 2014 - 2019: Segment, Animal type and Regional Analysis
M2 - Tue Sep 16, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/knrxpc/animal_healthcare) has announced the addition of the "Animal Healthcare Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019 Market" report to their offering. The global animal healthcare market is growing due to the increasing animal population of both types: companion and production. Companion animals are those which people tame or adopt for companionship, house/office guards and production animals are raised for meat and milk-related products. The new diseases in animals and their transfer to humans via their product consumption and companionship are also propelling the animal healthcare market globally. However, some challenges have emerged in the form of regulations against the excess use of antibiotics in production animals, and legislations and protest of animal activists and institutions against animal research. The animal healthcare market is very competitive with the top ten players accounting for about 75% of the market and every company focusing on research and development to produce better pharmaceutical and vaccine products for the existing diseases. The animal healthcare market is categorized under three broad segments, namely feed additives, pharmaceuticals and vaccines. Feed additives can be categorized as nutritional feed additives and medicinal feed additives. Nutritional feed additives comprise amino acids, minerals and vitamins and are used for production animals for their optimal growth. Medicinal feed additives comprise hormones, enzymes, immune-modulators, probiotics and prebiotics and feed acidifiers which target specific diseases in production and companion animals. Pharmaceutical products mainly include endoparasiticides, ectoparasiticides, endectocides, antibiotics, anti-inflammatories and medicines for reproductive problems. Vaccines make animals disease-immune for a particular disease. In biological terms, vaccination against a particular pathogen aims to mimic the development of naturally acquired immunity by inoculation of non-pathogenic but immunogenic components of that pathogen.omponents of that pathogen. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Animal Healthcare Market - Industry Overview Chapter 4 Global Animal Healthcare Market: By Product Segment Chapter 5 Global Animal Healthcare Market: By Animal Type Chapter 6 Global Animal Healthcare Market: By Region Chapter 7 Competitive Landscape Chapter 8 Company Profiles - Bayer AG - Boehringer Ingelheim GmbH - Ceva Sant? Animale - Elanco Products Company - MERIAL Limited - Merck & Co., Inc. - Novartis Animal Health Inc. - Virbac SA - V?toquinol SA - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/kn...healthcare
Merck Serono to Broaden Its General Medicines Portfolio in Emerging Markets with Affordable, High-Quality Medicines
Business Wire - Tue Sep 16, 4:00AM CDT
--Lupin will provide product dossiers and supply finished products for portfolio expansion
Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis
Business Wire - Mon Sep 15, 12:30PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Merck's investigational once-weekly cathepsin K inhibitor. In the Long-Term Odanacatib Fracture Trial (LOFT), odanacatib met its primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with placebo. The results from this trial were presented today at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Houston, Texas.
New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma
PR Newswire - Mon Sep 15, 8:15AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Medtronic, Inc. (NYSE: MDT), Pharmacyclics Inc. (NASDAQ: PCYC) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6464-100free.
BeiGene Receives Clinical Milestone Payment for Development of BGB-290
Business Wire - Mon Sep 15, 7:00AM CDT
BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-290, an investigational poly (ADP-ribose) polymerase (PARP) inhibitor candidate currently in Phase 1 development. The milestone triggers a US$ 9 million payment from Merck to BeiGene.
Merck Millipore Recognized for Technologically Advanced Products by R&D Magazine
Business Wire - Mon Sep 15, 1:00AM CDT
Merck Millipore, the Life Science division of Merck, announced it has received two R&D Magazine 100 Awards for innovative products released to market in 2014. The 52nd Annual R&D Awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.
Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies
at The Street - Fri Sep 12, 10:32AM CDT
Here are some numbers to help investors make prudent decisions when allocating cash to 11 big-cap pharmaceutical companies.
Dow 30 Stock Roundup: Boeing Bags $11B Order, GE to Sell Appliance Unit to Electrolux - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Sep 12, 9:50AM CDT
The Dow had a dismal week as energy prices continued to dominate proceedings.
Research and Markets: Global Asthma Market 2014-2018: Leading Vendors are AstraZeneca, F. Hoffmann-La Roche, GSK, Merck & Novartis
Business Wire - Fri Sep 12, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/572r9k/global_asthma) has announced the addition of the "Global Asthma Market 2014-2018" report to their offering.
Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer
PR Newswire Europe - Fri Sep 12, 9:08AM CDT
DARMSTADT, Germany, September 12, 2014 /PRNewswire/ --
Global Animal Health Market 2014-2018: Key Vendors are Bayer, Elanco, Merck Animal Health, Merial and Zoetis
PR Newswire Europe - Fri Sep 12, 7:02AM CDT
DUBLIN, Sept. 12, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/jr5z25/global_animal] has announced the addition of the "Global Animal Health Market 2014-2018" [http://www.researchandmarkets.com/research/jr5z25/global_animal] report to their offering.
Global Asthma Market 2014-2018: Leading Vendors are AstraZeneca, F. Hoffmann-La Roche, GSK, Merck & Novartis
M2 - Fri Sep 12, 6:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/69j7kn/global_asthma) has announced the addition of the "Global Asthma Market 2014-2018" report to their offering. The Global Asthma Market to grow at a CAGR of 4.5% over the period 2013-2018. One trend emerging in this market is the use of combination therapies for the treatment of asthma patients. These therapies can improve patient condition in persistent asthma and act via reduction of the symptoms by controlling inflammation in the respiratory tract. According to the report, the major driving factor of this market is a rise in the prevalence of environmental pollution. Globalization and urbanization coupled with industrialization lead to an increase in environmental pollution. Further, the report states that the unknown etiology of the disease is a major challenge to the market which makes it difficult for drug manufacturers to develop a remedy. The underlying causes of asthma are not completely understood, though allergens and pollutants worsen the condition of the patient. This report covers the present scenario and the growth prospects of the Global Asthma market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various class of drugs used in the treatment of asthma: - Bronchodilators - Leukotriene antagonists - Mast cell stabilizers - Immunosuppressants Key Vendors - AstraZeneca - F. Hoffmann-La Roche - GlaxoSmithKline - Merck - Novartis Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Class of Drugs - Global Bronchodilators Market - Global Leukotriene Antagonists Market - Global Mast Cell Stabilizers Market - Global Immunosuppressants Market - Global Combination of ICS/LABA Market - Global Other Asthma Drugs Market - Geographical Segmentation - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Pipeline Portfolio - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/69...bal_asthma
Global Animal Vaccines Market 2014-2018: Leading Vendors are Bayer HealthCare, Elanco Animal Health, Merck Animal Health, Novartis Animal Health, Sanofi & Zoetis
M2 - Fri Sep 12, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/56q7l6/global_animal) has announced the addition of the "Global Animal Vaccines Market 2014-2018" report to their offering. The Global Animal Vaccines market to grow at a CAGR of 8.25% over the period 2013-2018 This report covers the present scenario and the growth prospects of the Global Animal Vaccines market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various animal vaccines. In terms of vaccines types, the Global Animal Vaccines market can be segmented into six: Companion Animal Vaccines, Livestock Vaccines, Porcine Vaccines, Poultry Vaccines, Equine Vaccines, and Other Animal Vaccines. One of the major emerging trends in this market is an increase in acquisitions. Vendors have been focusing on acquisitions to increase their foothold in the market through increased investments. According to the report, one of the main drivers of this market is an increase in the prevalence of animal diseases worldwide, in both developed and developing countries. As a result, the use of animal vaccines has increased. The increasing susceptibility of animals to chronic diseases has driven the revenue growth of this market to a great extent. Further, the report states that one of the main challenges that the market faces is a rise in the maintenance costs of vaccines. Though the animal vaccines have numerous benefits, the high cost of these vaccines hinders acceptability among end-users. Key Vendors - Bayer HealthCare - Elanco Animal Health - Merck Animal Health - Novartis Animal Health - Sanofi - Zoetis Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Products - Market Segmentation by Technology - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/56...bal_animal
